CryoPort, Inc. $CYRX Shares Sold by Brown Capital Management LLC

Brown Capital Management LLC trimmed its holdings in shares of CryoPort, Inc. (NASDAQ:CYRX) by 31.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,621,844 shares of the company’s stock after selling 1,177,118 shares during the period. Brown Capital Management LLC owned about 5.24% of CryoPort worth $24,855,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Assenagon Asset Management S.A. increased its holdings in shares of CryoPort by 37.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock valued at $14,208,000 after purchasing an additional 408,263 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in CryoPort during the second quarter worth about $123,000. Y Intercept Hong Kong Ltd acquired a new position in CryoPort during the second quarter worth about $292,000. Conestoga Capital Advisors LLC lifted its position in shares of CryoPort by 55.9% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 110,557 shares of the company’s stock valued at $825,000 after acquiring an additional 39,640 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of CryoPort by 663.2% during the 3rd quarter. SG Americas Securities LLC now owns 127,280 shares of the company’s stock valued at $1,207,000 after acquiring an additional 110,602 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CYRX has been the topic of a number of research reports. Needham & Company LLC upped their price target on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. UBS Group boosted their target price on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, CryoPort currently has an average rating of “Moderate Buy” and an average price target of $12.83.

Insider Activity

In related news, Director Ramkumar Mandalam sold 11,570 shares of the firm’s stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total transaction of $115,584.30. Following the sale, the director owned 80,758 shares in the company, valued at approximately $806,772.42. This trade represents a 12.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.10% of the company’s stock.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $9.62 on Tuesday. The business’s fifty day moving average price is $9.93 and its two-hundred day moving average price is $9.30. The stock has a market cap of $481.67 million, a PE ratio of 8.22 and a beta of 1.66. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77. CryoPort, Inc. has a one year low of $4.58 and a one year high of $11.45.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%.The company had revenue of $44.23 million during the quarter, compared to analysts’ expectations of $41.22 million. On average, analysts forecast that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.